Formulation and Evaluation of Ketotifen Fumarate Fast Disintegrating Sublingual Tablets



The aim of this study was to formulate KF fast disintegrating sublingual tablets (FDSLTs).  KF has an oral bioavailability of only 50%, as it undergoes first pass metabolism in liver. Sublingual dosage form bypasses the metabolism of KF in liver and offers a fast relieve of asthma also it is not swallowed thus; improve the patient compliance especially for geriatric and pediatric patients, because of swallowing difficulties. To achieve this goal, superdisintegrants and diluents were evaluated for their effect on the disintegration behavior of KF fast disintegrating sublingual tablets. In addition, of enhancing the permeability and bioavailability of selected formulae through comlexation with 2-HP-β-CD.   A 24 full factorial design was applied for a screening study in which four factors were used at two levels.  Two of these factors, were the type of disintegrants; Ac-di-sol or Explotab, and the concentration of each disintegrant (3% or 5%w/w).  10%w/w Avicel PH101 or PEG6000 was used as binder and the filler was either spray dried lactose or granular mannitol. The weight variation, content uniformity, friability, hardness, disintegration time, and in-vitro dissolution of the prepared formulae were evaluated.  The formula F9 containing 5%w/w Ac-di-sol with 10%w/wAvicel PH101and granular mannitol as diluent which has the least disintegration time (about 20 seconds) and the highest dissolution rate was selected as best formula for bioequivalence study.  The mean plasma concentration–time courses for KF following the administration of FDSLTs  F9 (contains KF without compelxation with 2HP-βCD), Fc9 (contains KF/2HP-βCD complex) and Zaditen® (Novartis-Egypt) tablets  in six healthy male volunteers were found to be different following the three treatments, expressed with  higher Cmax by about 60% and 90% for both FDSLTs of F9 and Fc9 respectively,  and earlier tmax (by 1 h) values for  both of  FDSLTs F9 and Fc9 compared with Zaditen tablets. The relative bioavailability of Fc9 was 152.45% compared to 130.304% for F9 when Zaditen® tablets were taken as reference standard. The results indicate that KF/2-HP-βCD fast disintegrating sublingual tablets may serve as a successful strategy for enhancing the bioavailability of KF.


Sublingual tablets, Ketotifen Fumarate, 2-HP-βCD, Fast disintegration, Bioavailability

Full Text:



Shojaei, A.H., Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci., 1998. 1(1): p. 15-30.

El-Hawary, M., Khayal, M. and Issak, Z., in: “Handbook of Pharmacology”, . 1985. 377-384.

“Martindale; The Complete Drug Reference” ,Sean, C. Sweetman, . 2002, 33rd Ed.,The Pharmaceutical Press, London,. p.759-767.

“USP DI: Advice for the Patient Drug Information in Lay Language” Vol. II. 2001, 21st. Ed., MICROMEDEX, Thomson Healthcare. p. 920-921.

Yang, S., Fu, Y., Jeong, H.S., and Park, K., Application of polyacrilic superporous hydrogel microparticles as a sper-disintegrant in fast disintegrating tablets. J.P.P, 2004. 56: p. 429-436.

Del Valle, E.M.M., Cyclodextrins and their uses. a review. Process Biochemistry, 2004. 39: p. 1033-1046.

Challa, R., Ahuja, A., Ali, J. , and Khar, R.K., Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech , Article 34, 2005. 6(2): p. E329-E357.

Nagarsenker, M.S., Meshram, R.N. and Ramprakash, G., Solid dispersion of hydroxypropyl beta-cyclodextrin and ketorolac: enhancement of in-vitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenicity in rats. J. Pharm. Pharmacol., 2000. 52(8): p.


Szejtli, J.a.S., L., Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins. Eur. J. Pharm. Biopharm, 2005. 61(3): p. 115-125.

Arima, H., et al., Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci, 2001. 90(6): p. 690-701.

The Biritich Pharmacopoia. 2001: Vol. I and Il .London :The statiory office,. p.705-706,1810-1812

Ansel , H.C., Allen ,L.V. ,and Popovich ,N.G. , Pharmaceutical Dosage Form and Drug Delivery Systems". 7th ed. 1999: Philadelphia: Lippincott Wilkins ,Wolters Kluwer Company. p. 60-63.

Kottke, M.K. and E.M. Rudnic, Tablet Dosage Forms, in Modern Pharmaceutics, G.S. Banker, and Rhodes, C.T., Editor. 2002, Marcel Dekker Inc.: New York. p. 437-511.

Alderborn, G., Tablets and compaction, in Pharmaceutics The Science of Dosage Form Design, M.E. Aulton, Editor. 2002, Churchill Livingstone: Edinburgh. p. 397-439.

Abd El-Bary, A.A., Salem, H.F., Kharshoum, R.M., 2-Hydroxypropyl-ß-Cyclodextrin Complex with Ketotifen Fumerate for Eye Drops Preparations. International Journal of Drug Delivery, 2011. 3: p. 228-240.

Chiang, C.H., Chen, J.L., Liu, Y.T. , Therabutic effectband pharmacokineticsof ketotifen trans dermal delivary system. Drug Dev. Indust. Pharm., 1998. 24: p. 213-217.

Tapash, K., Ghosh and Pfister, W.R., Drug delivery to the oral cavity Molecules to the market. Taylor & Francis Group, 2005.

Conine, J.W., and Pikal.M.J., Pharmacutical Dosage FormsTablets, ed. H.A. Liberman, Lachman, L.,Schwartz J.B. Vol. 1. 1989: New York :Marcel Dekker. p.329-340.

Jacobsen, J., Christrup, L., and Jensen, N., Medicated chewing gum: pros and cons Am J Drug Delivery, 2004. 2(2): p. 75-88.

Seager, H., Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol,, 1998. 50(4): p. 375-382.

Loftsson, T., Jarho, P., Masson, M., and Jarvinen, T, Cyclodextrins in drug delivery. Exp. Opinion Drug Del, 2005. 2: p. 335-351.

Senel, S., and Hincal, A.A., Drug permeation enhancement via. buccal route: Possibilities and limitations. J. Control. Rel., 2001. 72: p. 133-144.

Vandecruys, R., Peeters, J., Verreck, G. and Brewster, M.E. , Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. Int. J. Pharm., 2007. 342(1-2): p. 168-175.

Yoo, S.D., Yoon, B.M., Lee, H.S. and Lee, K.C., Increased bioavailability of clomipramine after sublingual administration in rats. J. Pharm. Sci. , 1999. 88(11): p. 1119-1121.

Udata, C., Patel, J., Pal, D., Hejchman, E., Cushman, M. and Mitra, A.K., Enhanced transport of a novel anti-HIV agent--cosalane and its congeners across human intestinal epithelial (Caco-2) cell monolayers. Int. J. Pharm. , 2003. 250(1): p. 157-168.

Martins, P.S., Ochoa, R., Pimenta, A.M., Ferreira, L.A., Melo, A.L., da Silva, J.B., Sinisterra, R.D., Demicheli, C. and Frézard, F., Mode of action of beta-cyclodextrin as an absorption enhancer of the water-soluble drug meglumine antimoniate. Int. J. Pharm., 2006. 325(1-2): p. 39-47.


  • There are currently no refbacks.

Copyright (c)

               AR Journals

18K, Street 1st, Gaytri Vihar, Pinto Park, Gwalior, M.P. India (Design) 2009-2021


Follow @arjournals on Twitter